<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182141</url>
  </required_header>
  <id_info>
    <org_study_id>1199.2</org_study_id>
    <nct_id>NCT02182141</nct_id>
  </id_info>
  <brief_title>An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120,
      pharmacodynamics
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>Up to 11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events according to Common Toxicity Criteria (CTC) associated with increasing doses of BIBF 1120</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory parameters</measure>
    <time_frame>Baseline, up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response in surrogate markers</measure>
    <time_frame>Baseline, up to 11 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 2h (C2,1)</measure>
    <time_frame>2 hours after first administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cellular protein tyrosine kinase inhibition</measure>
    <time_frame>Baseline, up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance score</measure>
    <time_frame>Baseline, up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG)</measure>
    <time_frame>Baseline, up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration immediately before administration of the Nth dose over the dosing interval τ (Cpre,N)</measure>
    <time_frame>Up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve during the dosing interval τ (24 h) at steady state (AUCτ,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration at the time point immediately before dosing at steady state (Cpre,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration during the dosing interval τ at steady state (Cmin,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration during the dosing interval τ at steady state (Cmax,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach minimum plasma concentration during the dosing interval τ at steady state (tmin,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration during the dosing interval τ at steady state (tmax,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life at steady state (t1/2,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma clearance at steady state (CL/F,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time at steady state (MRTpo,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response assessed according to the European Group for Blood and Marrow Transplantation (EBMT) criteria</measure>
    <time_frame>Up to 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>BIBF 1120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120 ES</intervention_name>
    <arm_group_label>BIBF 1120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with confirmed diagnosis of multiple myeloma, who did not respond to or
             relapsed after either anthracyclines and pulsed glucocorticoids or high-dose therapy
             and who are currently not eligible for transplant modalities.

          2. Age 18 years or older

          3. Life expectancy of at least six months

          4. Patients have to give written informed consent (which must be consistent with ICH-GCP
             and local legislation)

          5. Eastern Cooperative Oncology Group (ECOG) performance score &lt;2.

          6. Recovery from all therapy-related toxicities from previous chemo-, immuno- or
             radiotherapies.

        Exclusion Criteria:

          1. History of relevant surgical procedures during the last four weeks prior to treatment
             with the trial drug, or active ulcers, fractures or injuries with incomplete healing

          2. Active infectious disease

          3. Uncontrolled, severe hypertension

          4. Gastrointestinal disorders anticipated to interfere with the resorption of the study
             drug

          5. Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          6. Absolute neutrophil count less than 1000 / mm³.

          7. Platelet count less than 30 000 / mm³

          8. Conjugated Bilirubin greater than 2 mg / dl (&gt; 34 μmol/L, SI unit equivalent)

          9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than three times the upper limit of normal

         10. Endogenous creatinine clearance (ECC) &lt;20 ml/min

         11. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         12. Pregnancy or breastfeeding

         13. Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

         14. Patients unable to comply with the protocol

         15. Active alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

